Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126849531 | 12684953 | 1 | I | 20160729 | 20160818 | 20160825 | 20160825 | EXP | US-ASTELLAS-2016US032671 | ASTELLAS | 60.00 | YR | M | Y | 0.00000 | 20160825 | CN | GB | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126849531 | 12684953 | 1 | PS | TARCEVA | ERLOTINIB HYDROCHLORIDE | 1 | Oral | 21743 | 150 | MG | FORMULATION UNKNOWN | QD | |||||||
126849531 | 12684953 | 2 | SS | DILANTIN | PHENYTOIN | 1 | Unknown | UNK UNK, UNKNOWN FREQ. | U | 0 | FORMULATION UNKNOWN |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126849531 | 12684953 | 1 | Renal cancer |
126849531 | 12684953 | 2 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126849531 | 12684953 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126849531 | 12684953 | Dizziness | |
126849531 | 12684953 | Drug level increased | |
126849531 | 12684953 | Muscular weakness |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126849531 | 12684953 | 1 | 20160723 | 0 |